Exonate - company
Founded 2013 · 17 employees on LinkedIn · 8 known investors
Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.
Founders & leadership
OH
Olav HellebøChief Executive Officer
Investors · 8
Frequently asked questions
- What does Exonate - company do?
- Exonate is a biotechnology company developing treatments for retinal vascular diseases, with a lead asset (EXN407) intended as a topical therapy for diabetic retinopathy and diabetic macular oedema. The drug is set to enter Phase IIb clinical trials in 2026.
- Who are Exonate - company's investors?
- Exonate - company's investors include O2h Ventures, Wellcome Trust, Wren Capital, Cambridge Angels group, EMV Capital, Martlet Capital, Stoic VC, UniSeed Pty Ltd..